- Home
- MLYS vs PLRX Comparison
MLYS vs PLRX Comparison
Compare MLYS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- PLRX
- Stock Information
- Founded
- MLYS 2019
- PLRX 2015
- Country
- MLYS United States
- PLRX United States
- Employees
- MLYS N/A
- PLRX N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MLYS Health Care
- PLRX Health Care
- Exchange
- MLYS Nasdaq
- PLRX Nasdaq
- Market Cap
- MLYS 526.1M
- PLRX 680.3M
- IPO Year
- MLYS 2023
- PLRX 2020
- Fundamental
- Price
- MLYS $10.21
- PLRX $11.37
- Analyst Decision
- MLYS Strong Buy
- PLRX Strong Buy
- Analyst Count
- MLYS 2
- PLRX 7
- Target Price
- MLYS $30.00
- PLRX $40.50
- AVG Volume (30 Days)
- MLYS 263.5K
- PLRX 485.5K
- Earning Date
- MLYS 03-20-2025
- PLRX 02-26-2025
- Dividend Yield
- MLYS N/A
- PLRX N/A
- EPS Growth
- MLYS N/A
- PLRX N/A
- EPS
- MLYS N/A
- PLRX N/A
- Revenue
- MLYS N/A
- PLRX N/A
- Revenue This Year
- MLYS N/A
- PLRX N/A
- Revenue Next Year
- MLYS N/A
- PLRX N/A
- P/E Ratio
- MLYS N/A
- PLRX N/A
- Revenue Growth
- MLYS N/A
- PLRX N/A
- 52 Week Low
- MLYS $8.58
- PLRX $10.22
- 52 Week High
- MLYS $16.91
- PLRX $18.00
- Technical
- Relative Strength Index (RSI)
- MLYS 44.53
- PLRX 44.60
- Support Level
- MLYS $9.57
- PLRX $10.35
- Resistance Level
- MLYS $10.79
- PLRX $11.07
- Average True Range (ATR)
- MLYS 0.64
- PLRX 0.61
- MACD
- MLYS 0.11
- PLRX 0.06
- Stochastic Oscillator
- MLYS 63.98
- PLRX 43.50
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.